Faculty Opinions recommendation of Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma.

Purpose. To compare the visual and anatomic outcomes in patients with persistent diabetic macular edema (DME) who switched from ranibizumab to aflibercept with those who continued with previous ranibizumab therapy. Methods. In this retrospective comparative study, medical records of consecutive patients with center-involved DME ≥ 350 μm who had at least three recent consecutive monthly ranibizumab injections followed by as-needed therapy with either aflibercept or ranibizumab were reviewed. Data were collected at presentation (preinjection), at the intermediary visit, and at the last visit (at the end of the follow-up period). Results. Forty-three eyes of 43 patients were divided into two groups: the switch group (n=20) and the ranibizumab group (n=23). Though no significant improvement was found in the mean BCVA from the intermediary visit to the last visit, there was a difference in the mean CMT in the switch group and the ranibizumab group (p<0.001 and p=0.03, resp.). The mean CMT decreased after the intermediary visit by 188.6 ± 120.5 μm in the switch group and by 60.3 ± 117.1 μm in the ranibizumab group (p=0.003). Conclusions. Both aflibercept and ranibizumab decreased CMT in patients with persistent DME who showed a poor response to ranibizumab injections. However, switching to aflibercept provided only morphologic improvement.

Download Full-text

Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study

American Journal of Ophthalmology ◽

10.1016/j.ajo.2014.07.027 ◽

2014 ◽

Vol 158 (5) ◽

pp. 1032-1038.e2 ◽

Cited By ~ 78

Author(s):

Yuichiro Ogura ◽

Johann Roider ◽

Jean-François Korobelnik ◽

Frank G. Holz ◽

Christian Simader ◽

...

Keyword(s):

Macular Edema ◽

Retinal Vein Occlusion ◽

Central Retinal Vein Occlusion ◽

Phase 3 ◽

Vein Occlusion ◽

Intravitreal Aflibercept ◽

Central Retinal Vein

Download Full-text

Fungal granuloma following ruthenium plaque radiotherapy of a choroidal melanoma

Clinical and Experimental Ophthalmology ◽

10.1046/j.1442-9071.2003.00625.x ◽

2003 ◽

Vol 31 (2) ◽

pp. 159-161 ◽

Cited By ~ 3

Author(s):

Salim Okera ◽

Tom Dodd ◽

Dinesh Selva ◽

James Muecke

Keyword(s):

Choroidal Melanoma ◽

Plaque Radiotherapy

Download Full-text

Radiation Macular Edema after Ru-106 Plaque Brachytherapy for Choroidal Melanoma Resolved by an Intravitreal Dexamethasone 0.7-mg Implant

Case Reports in Ophthalmology ◽

10.1159/000337144 ◽

2012 ◽

Vol 3 (1) ◽

pp. 71-76 ◽

Cited By ~ 14

Author(s):

Andrea Russo ◽

Teresio Avitabile ◽

Maurizio Uva ◽

Salvatore Faro ◽

Livio Franco ◽

...

Keyword(s):

Macular Edema ◽

Choroidal Melanoma ◽

Intravitreal Dexamethasone ◽

Plaque Brachytherapy

Download Full-text

Aflibercept or ranibizumab for the treatment of diabetic macular edema; a retrospective study

International Journal of Research in Pharmaceutical Sciences ◽

10.26452/ijrps.v10i4.1586 ◽

2019 ◽

Vol 10 (4) ◽

pp. 3000-3005

Author(s):

Khlood M. Aldossary ◽

Anfal Alruzuq ◽

Ghady Almohanna ◽

Hessa Almusallam ◽

Sara Alamri ◽

...

Keyword(s):

Visual Acuity ◽

Macular Edema ◽

Diabetic Macular Edema ◽

Macular Thickness ◽

P Value ◽

Central Macular Thickness ◽

Intravitreal Ranibizumab ◽

Injectable Drugs ◽

Significant Difference ◽

Intravitreal Aflibercept

Diabetic macular edema (DME) is a significant cause of diabetic retinopathy and a major cause of vision loss. In this study, we aimed to evaluate and compare the efficacy of two injectable drugs; intravitreal Aflibercept and intravitreal Ranibizumab for the treatment of DME of the eyes. A retrospective chart review was conducted for patients diagnosed with DME from March 2014 to January 2019 who received either intravitreal Aflibercept or intravitreal Ranibizumab injection. A total of 57 eyes were included, of which 19 eyes were treated with intravitreal Ranibizumab injection, and 38 eyes were treated with intravitreal Aflibercept injection; all eyes were examined for 3 months. Two outcomes were assessed in this study, namely; visual acuity (VA) and central macular thickness (CMT). The mean age in the Ranibizumab group was 61.1±9.5 vs 64.3±10.2 in the Aflibercept group with no significant difference (p-value=0.25). The ratio of improvement in visual acuity (VA) in the Ranibizumab group was 68.4% vs 44.7% in the Aflibercept group; (p-value=0.038) which demonstrates the superiority of Ranibizumab over Aflibercept concerning visual acuity result. However, there is no statistically significant difference between the ratio of improvement in central macular thickness (CMT) results in both groups; (p-value=1.00). In fact, the ratio of improvement in CMT in both groups was the same 78.9% for both the groups. The pre and post results demonstrated improvement in post-procedural for CMT among both the groups but only Ranibizumab group showed VA improvement post-procedural. Through this study, we concluded that both injectable drugs improve visual acuity (VA) and decrease central macular thickness (CMT) in eyes with DME. However, Ranibizumab is superior in improving visual acuity compared to Aflibercept. Further comparative effectiveness trials between Aflibercept and Ranibizumab are still warranted.

Download Full-text